Preclinical, Publications Small molecule PD-L1 inhibitor ALG-093702, Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models
Preclinical, Publications siRNA PD-L1 inhibitor, A potent human PD-L1 siRNA leads to significant reduction of AAV-HBV infected hepatocytes via immune activation in human PD-1/PD-L1 double knock in mice
Preclinical, Publications Hepatitis B virus model system, An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients
Preclinical, Publications Hepatocellular carcinoma, Selective inhibition of human β-catenin DNA transactivation activity using splice switching oligonucleotides for an improved therapeutic window in treating hepatocellular carcinoma
Preclinical, Publications Discovery of a Liver-Targeted PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver Cancer
Preclinical, Publications Discovery of Liver-targeted Oral PD-L1 Small Molecule Inhibitors for the Treatment of Chronic Hepatitis B and Liver Cancers
Preclinical, Publications HAP Class I Capsid Assembly Modulators Clear Hepatitis B Virus-Infected Hepatocytes Through Core-dependent Hepatocyte Death and Subsequent Proliferation
Preclinical, Publications Non-HAP class I capsid assembly modulators have distinct profiles and a differentiated mechanism of action
Preclinical, Publications Suppression of PD-L1 expression by a novel liver-targeted siRNA leads to potential restoration of immune responses against HBV